Sildenafil
- Generic Name
- Sildenafil
- Brand Names
- Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O4S
- CAS Number
- 139755-83-2
- Unique Ingredient Identifier
- 3M7OB98Y7H
- Background
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...
- Indication
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:
(1) the treatment of erectile dysfunction ; and
(2) treatment of pulmonary hypertension, where:
...
- Associated Conditions
- Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Sildenafil in Hemodialysis Patients With Pulmonary Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT03763045
- Locations
- 🇪🇬
Ain Shams University Hospital, Cairo, Abbasia, Egypt
Endurance Performance at Altitude
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 10
- Registration Number
- NCT03710369
- Locations
- 🇨🇦
University of British Columbia - Environmental Physiology Laboratory, Vancouver, British Columbia, Canada
Improving Right Ventricular Function in Young Adults Born Preterm
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 10
- Registration Number
- NCT03696758
- Locations
- 🇺🇸
University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States
VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT03686306
- Locations
- 🇫🇷
Nîmes University Hospital, Nîmes, France
🇫🇷Caen University Hospital, Caen, France
🇫🇷Hospital Paris Saint-Joseph and Hospital Marie Lannelongue, Paris, France
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT03462017
- Locations
- 🇩🇪
Investigational Site Number 2760001, Neuss, Germany
🇩🇪Investigational Site Number 2760002, Mainz, Germany
Sildenafil in US Heart Failure Patients (SilHF-US)
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT03460470
- Locations
- 🇺🇸
Hartford Hospital 80 Seymour street, Hartford, Connecticut, United States
L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 60
- Registration Number
- NCT03402191
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Revatio Special Investigation for Long-term Use in Pediatric Patients
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Viatris Pharmaceuticals Japan Inc
- Target Recruit Count
- 1023
- Registration Number
- NCT03364244
- Locations
- 🇯🇵
Viatris Pharmaceuticals Japan Inc., 5-11-2; Toranomon, Minato-ku, Tokyo, Japan
Nivolumab With Chemotherapy in Refractory MDS
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 2
- Registration Number
- NCT03259516
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT03230162
- Locations
- 🇪🇬
AinShams university maternity hospital, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.